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Antibiotic susceptibilities of Haemophilus injluenxae in 
central Scotland 
Philippa M. A. Shanahan, Christopherj. Thomson and Sebastian G. B. Amyes 
Scottish Antibiotic Reference Laboratory, Department of Medical Microbiology, 
University of Edinburgh, Edinburgh, U K  
Objective: To ascertain the incidence of antibiotic resistance in Haernophilus influenzae in  central Scotland and the p- 
lactamases produced by these isolates. 
Methods: A total of 213 H. influenzae isolates from four medical centers in Scotland [Aberdeen ( n  = 58), Edinburgh 
( n  = 55). Glasgow ( n  = 64) and Dundee ( n  = 36)l were tested for susceptibility to a range of antimicrobials including p- 
lactams, p-lactamlp-lactamase-inhibitor combinations, and a representative 4-quinolone, antifolate and macrolide. 
Susceptibility testing of the p-lactam/p-lactamase-inhibitor combination amoxicillin plus clavulanic acid was conducted 
at both 2:l and 4:l ratios and with clavulanic acid fixed at a concentration of 2 mg/L. Each strain was further investigated 
for the presence of P-lactamase activity. 
Results: Although the incidence of resistance to amoxicillin was 15%. in  the presence of clavulanic acid, this resistance 
was reduced to  4.2%. 5.6% and 4.2% with the 2:l ratio, 4:l ratio and 2 mg/L fixed concentration, respectively. Sixteen 
percent of the isolates demonstrated immediate P-lactamase production. lsoelectric focusing showed that 77.4%, 16.1% 
and 6.5% of the P-lactamase-positive strains were found to  contain TEM-1, VAT-I and both TEM-1 and VAT-I p- 
lactamases, respectively. A further 29% of the strains were recognized as being P-lactamase-positive after prolonged 
incubation with nitrocephin. 
Conclusions: This study suggests that current testing for P-lactamases may underestimate the prevalence of p- 
lactamase production in H. influenzae. 
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Haernophilus influenzae is a major cause of systemic 
disease as well as upper and lower respiratory tract 
infections [l]. This organism is, however, carried as a 
commensal in the throat of 80% of healthy individuals, 
frequently with multiple strains coinciding [2]. 
A number of studies have reported this pathogen 
to be increasingly resistant to antimicrobial agents, in 
particular, to the p-lactams [3-51. p-lactam resistance in 
H .  influenzae may result from changes in the outer 
membrane porins (OMPs) that reduce cell wall 
permeability, modification of the drug target or the 
production of P-lactamases [6,7]; the latter is generally 
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considered to be the most important mechanism of 
resistance. Among clinical isolates of H.  influenzae, 
plasmid-mediated TEM-1 is the most frequently 
isolated p-lactamase [8]. Previous studies have deter- 
mined that p-lactamase resistance in this organism may 
also result from the presence of ROB-I [9] and, more 
recently, VAT-1 p-lactamases [I 01. Whereas newer- 
generation cephalosporins or p-lactam/p-lactamase- 
inhibitor combinations may overcome p-lactamase 
resistance, these agents may still be compromised by the 
bacterial intrinsic resistance mechanisms [l l] .  
Because of the increase in the prevalence of 
resistance in H. influenzae, it is important to monitor 
antimicrobial activity and mechanisms of resistance 
to ascertain optimal therapy [12]. Amoxicillin plus 
clavulanic acid has been employed in the treatment 
of H.  influenzae infections. There has, however, been 
some debate as to the most appropriate sensitivity- 
testing ratio for this combination. The British Society 
for Chemotherapy states in its guidelines that this 
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combination may be tested at either a 2:l ratio 
(anioxicil1in:clavulanic acid) or with clavulanic acid 
fixed at 2 mg/L 1131. In comparison, the National 
Committee for Clinical Laboratory Standards (NCCLS) 
guidelines recommend that testing be performed only 
at a 2:l ratio [14]. In France, testing is conducted with 
clavulanic acid fixed a t  a concentration of 2 mg/L [I 51. 
In this study, the susceptibility of H .  influenzae 
isolates from four medical centers in Scotland to three 
different combinations of amoxicillin plus clavulanic 
acid was examined and the activity compared with a 
range of cephalosporin agents. In addition, the p- 
lactarnases responsible for mediating resistance in these 
strains was investigated. 
MATERIALS AND METHODS 
Bacterial strain collection and identification 
A total of 213 H .  influenzae strains were obtained from 
four major teaching hospitals in Scotland-Aberdeen 
Royal Trust Hospital, Ninewells Hospital Dundee, 
Edinburgh Royal Infirmary and Glasgow Royal 
Infirmary. Identification of the H .  influenzae strains was 
confirmed by the use of x (hernin), v (nicotinaniide- 
adenine dinucleotide; NAD) and xv growth-factor 
disks (Medical Wire and Equipment Co., Bath, UK) on 
nutrient agar plates according to the manufacturer’s 
instructions. 
Antibiotics 
The antibiotics included in the study were: clavulanic 
acid and anioxicillin (both from SmithKline Beechani 
Pharmaceuticals, Hertfordshire, UK); cefaclor (Eli Lilly 
Company, Indianapolis, IN); cefuroxime (Glaxo- 
Wellcome, Greenford, UK); ciprofloxacin (Bayer, 
Newbury, UK); trimethoprim (GlaxoWellconie, 
Greenford, UK); azithroniycin (Pfizer Pharmaceuticals, 
Ringaskiddy, Ireland); and cefixinie, piperacillin and 
tazobactarn (all from Lederle Laboratories, Gosport, 
UK) . 
medium, and approximately lo3 CFU was inoculated 
onto the surface of each test plate with a Denley 
niultipoint inoculator. The MIC was defined as the 
lowest concentration of antibiotic that inhibited visible 
growth after overnight incubation at 37°C in 5% 
carbon dioxide (C02). The MIC of arnoxicillin plus 
clavulanic acid was performed at ratios of 4:l and 2:l 
(arnoxicil1in:clavulanic acid), and with 2 nig/L fixed 
clavulanic acid, and expressed in terms of the 
amoxicillin concentration. 
p-lactamase identification 
Each isolate was inoculated onto the surface of a 10- 
mL Columbia agar base (Oxoid, CM) slope containing 
5% w/v defibrinated horse blood and incubated 
overnight at 37°C in 5% C02. Cells were washed from 
the surface of each slope and suspended in 1 rnL 
volumes of 50 mM sodium phophate buffer (pH 7.0). 
As described elsewhere [ 161, sonicated P-lactaniase 
extracts were prepared from the cells and each extract 
spot-tested for P-lactamase activity with a 50 mg/L 
solution of nitrocephin. A color change of the nitro- 
cephin solution from yellow to red within 10 niin was 
considered a positive reaction. To identify weak p- 
lactaniase activity, all of the p-lactaniasc extracts were 
subjected to prolonged incubation with nitrocephin 
over a 24-h period. p-lactaniase preparations were 
prepared from known p-lactamase-negative strains and 
included as negative controls. The P-lactaniases were 
identified by analytical isoelectric focusing and after 
visualization with nitrocephin (1 0-3 M) compared with 
known p-lactamases isolated from control strains. The 
standard p-lactamase-producing strains employed as 
controls were Esrhevicjlia coli K12 562-2 containing 
plasmid R 1  (TEM-l), plasmid RP4 (TEM-2), and 
plasmid KlOlO (SHV-l), and H. influenzae encoding 
VAT-I. (VAT-1 was kindly provided by L. Vali, Uni- 
versity of Edinburgh, Scotland, UK.) 
Minimum inhibitory concentration 
Minimuin inhibitory concentration (MIC) plates were 
made with doubling dilutions of each antimicrobial 
agent in Columbia agar base (Oxoid, Basingstoke, UK) 
containing 5% w/v defibrinated horse blood. For each 
antimicrobial agent, the drug concentration range 
tested was as recommended in the British Society of 
Antimicrobial Chemotherapy (BSAC) guidelines [13]. 
An overnight culture of each organism in brain-heart 
infusion (BHI) broth (Oxoid C M  225) supplem nted 
with p-NAD (10 mg/L) and bovine heniin (10 mg/L) 
was diluted in Davis and Mingioli (DM) minimal 
Bacterial strains 
A total of 213 H .  injuenzae isolates were included in 
the study: 58 from Aberdeen Royal Infirmary; 36 from 
Ninewells Hospital l hndee ;  55 from Edinburgh Royal 
Infirmary; and 64 from Glasgow Royal Infirmary. The 
integrity of each strain as H. influenzae was confirmed 
as described in the materials and methods section. 
Susceptibility testing 
The MIC of each antibiotic for all isolates has been sum- 
niarized with MI& and MICyo values (Tables 1 and 
2). The collective MIC data from all centers (Table 1) 
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Table 1 Minimum inhibitory concentrations (MIC) of a 
range of antibiotics in Haernophilus infnenzae from all study 
centers 
Antibiotic MIC5o MICro Range 
Amoxicillin 0.5 2 0.06 - > 128 
A/C at 2:l 0.5 1 0.06 - > 2 
A/C at 4:l 0.5 1 0.06 - > 2 
A/C fixed 2 mg/L 0.5 1 0.06 - > 2 
Cefaclor 4 8 0.25 - > 16 
Cefixime 0.25 0.25 0.25 - 0.5 
Cefuroxime 0.5 2 0.25 - 16 
Ciprofloxacin 0.008 0.016 0.002 - > 0.032 
Trimethoprim 0.125 1 0.015 - > 16 
Azithromycin 1 1 0.12 - 4 
P/T fixed 4 mg/L 0.008 0.0312 0.004 - > 2 
A/C = amoxicillin plus clavulanic acid; P/T = piperacillin plus 
tazobactam. 
show no variation in either the MICSO (0.5 mg/L) or 
MICw (1 mg/L) results between the different ratios of 
amoxicillin plus clavulanic acid. When each of the 
centers is considered separately (Table 2), only the 
isolates from Aberdeen exhibited variations in MICso 
and MIC90 values with the different ratios of the 
combination, increasing from 0.25 mg/L and 0.5 mg/L 
to 0.5 mg/L and 1 mg/L, respectively, with the 4:l 
ratio. The in-vitro efficacy of the combination was, in 
all cases, found to be greater than the efficacy of 
amoxicillin alone. 
The MICs0 and MIC90 values suggest that the 
prevalence of resistance to each of the other anti- 
bacterials tested was slightly higher among those 
isolates obtained from Dundee than any other center 
Table 2 Minimum inhibitory concentrations (MIC) of a range of antibiotics in Haernophilus infuenzae from individual study 
centers 
Antibiotic 
Aberdeen Dundee Edinburgh Glasgow 
MICso MICpij MICjo MICpo MICso MICyo MICjo MICw 
Amoxicillin 0.5 1 1 2 0.5 4 0.5 2 
A/C at 2.1 0.25 0.5 1 1 0.5 1 0.5 1 
A/C at 4.1 0.5 1 1 1 0.5 1 0.5 1 
A/C fixed 2 mg/L 0.25 0.5 1 1 0.5 1 0.5 1 
Cefaclor 4 4 4 >16 4 8 4 8 
Cefixime 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 
Cefuroxime 0.5 1 1 4 0.5 1 0.5 2 
Ciprofloxacin 0.008 0.016 0.008 0.016 0.008 0.008 0.008 0.008 
Trimethoprim 0.062 0.25 0.25 1 0.062 0.25 
P/T fixed 4 mg/L 0.008 0.016 
A/C = amoxicillin plus clavulanic acid; P/T = piperacillin plus tazobactam. 
0.125 0.5 
Azithromycin 0.5 1 1 2 0.5 1 0.5 1 
0.016 0.062 0.008 0.031 0.008 0.031 
Table 3 Percentage of antibiotic-resistant Haernophilus infuenzae at standard breakpoint levels 
Breakpoint All Aberdeen Dundee Edinburgh Glasgow 
Antibiotic value (mg/L)” ( n  = 213) (n  = 58) (n = 36) (n = 55) (n = 64) 
Amoxicillin 1 15.0 10.3 22.2 18.2 12.5 
A/C at 2.1 1 4.2 1.7 11.1 1.8 4.7 
A/C a t  4.1 1 5.6 1.7 11.1 7.3 4.7 
A/C fixed 2 mg/L 1 4.2 1.7 11.1 1.8 4.7 
Cefaclor 
Low 2 71.8 58.6 83.3 69.1 79.7 
High 8 9.9 3.4 27.7 5.5 9.4 
Cefixime 1 0 0 0 0 0 
Cefuroxime 
Low 1 10.3 1.7 22.2 9.1 12.5 
High 4 2.3 1.7 11.1 0 0 
Low 1 0.5 1.7 0 0 0 
High 4 0.5 1.7 0 0 0 
Low 0.5 10.3 8.6 25.0 5.5 7.8 
High 2 4.7 1.7 5.5 3.6 7.8 
Azithromycin 8h 0 0 0 0 0 
P/T fixed 4 mg/L 16 0 0 0 0 0 
Ciprofloxacin 
Trimethoprim 
a As recommended in the BSAC guidelines [13]; “As recommended by the manufacturer 
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(Table 2). I t  is apparent that the isolates from each 
center were largely sensitive to piperacillin plus 
tazobactam, the other p-lactam/p-lactamase-inhibitor 
combination tested. The MICso and MIC90 values 
were less than the breakpoint value for resistance 
recommended for this combination. Similarly, there 
was little resistance to the p-lactam cefixime, with 
MICs of < 0.25 mg/L for 90% of the strains tested. In 
addition, ciprofloxacin was highly active against all 
isolates (MICyo = 0.016 nig/L; Table 1). 
Table 3 shows the prevalence of antibiotic-resistant 
H. inzuenzae from all centers and from each center as 
determined by standard breakpoint levels; in this study, 
cefixime, azithromycin and ciprofloxacin performed 
particularly well. Indeed, only a single isolate from 
Aberdeen exhibited resistance to ciprofloxacin. A total 
of 15% of the H. injuenzae were resistant to anioxicillin 
(1 mg/L). In the presence of clavulanic acid, however, 
the prevalence of anioxicillin resistance was markedly 
reduced to 4.2% when the combination was tested at a 
2:l ratio or with clavulanic acid fixed at 2 mg/L. 
Testing at a 4:l ratio reduced anioxicillin resistance to 
5.6%. The BSAC guidelines recommend both low and 
high breakpoint values for some agents 1131. A large 
Table 4 Prevalence of p-lactamases in Haemophilus 
influenzae in each center 
All Aberdeen Ihndee  Edinburgh Glasgow 
(%) (%) (%) (“A) (%) 
TEM-1 24 (77.4) 9 (15.5) 1 (8.3) 9 (16.4) 5 (7.8) 
TEM- 1 / 
VAT-I 5 (16.1) 4 (6.9) 1 (5.3) 0 0 
VAT-1 2 (6.5) 2 (3.4) 0 0 0 
variation in resistance to cefaclor was observed between 
the low and high breakpoint values; the prevalence of 
resistance was 71.8% and 9.9% when 2 mg/L and 
8 mg/L, respectively, were used as breakpoint values. 
P-lactamase characterization 
Each isolate of H .  irlfluenzae was examined for the 
production of p-lactamases. Among the H .  infuenzae 
isolates, 15% responded positively within 10 niin to the 
nitrocephin P-lactaniase spot-test. Isoelectric focusing 
analysis of these P-lactamase-positive preparations 
identified two different p-lactamase types: those that 
cofocused with TEM-1 (77.4%); and those that co- 
focused with VAT-1 (16.1%). Two (6.5%) p-lactamase- 
positive preparations contained both of these enzymes. 
Whereas P-lactaniases cofocusing with TEM-1 were 
recognized in isolates obtained from all centers, p- 
lactaniases cofocusing with VAT-1 were only present in 
H. inzuenzae from Dundee and Aberdeen. In addition, 
only isolates from Aberdeen contained both enzyme 
types (Table 4). After prolonged incubation with 
nitrocephin over a 24-h period, a further 29% of all 
isolates exhibited a weak p-lactamase activity which, 
although not specifically investigated, was thought to 
be chroniosonially mediated. 
The p-lactam susceptibility of those organisms 
positive for p-lactamase production within a 1 0-min 
period was compared with the non-p-lactainase- 
producing strains (Table 5). As expected, except for 
low-level cefuroxinie (1 nig/L), the incidence of 
resistance for each agent tested was higher among the 
P-lactamase-positive strains. In this particular group, 
the addition of clavulanic acid markedly increased 
the efficiency of amoxicillin, decreasing resistance 
Table 5 Susceptibility of (13-lactaniase-positive and -negative strains to (13-lactam antibiotics in each study center 
Breakpoint All (“A) Aberdeen (%) Dundee (“h) Edinburgh (%) c;1a\gow ?XI) 
pos (oh) neg yk~) pos (“A) iieg (%) pos (74) nfs  (x) pos (%) neg (%) por yk,) neg (w) 
31 (14.6)h 182 (85.4)” 15 (25.9)‘‘ 43 (74.1)” 2 (5.6)” 34 (94.4)h 9 (16.4)“ 46 (83.6)” 5 (7.8)” 59 (92.2)” 
value (mg/L)d 
~ ~~ ~ 
Amoxicillin 
A / C  at 2:1 
A/C at 41  
A / C  fixed 2 mg/L 
Crfaclor 
Low 
High 
Cefixime 
Cefuroxsmc 
Low 
High 
P/T fixed 4 mg/L 
2 
8 
1 
1 
4 
16 
~ 
21 (67.7) 
2 (6.5) 
4 (12.9) 
2 (6.5) 
23 (74.2) 
0 
2 (6.5) 
3 (9.7) 
1 (3.2) 
0 
~ 
11 (6) 6 (40.0) 
8 (4.4) 1 (6.7) 
7 (3.8) 1 (6.7) 
130 (71.4) 11 (73.3) 
19 (10.4) 1 (6.7) 
0 0 
7 (3.8) 1 (6.7) 
19 (10.4) 1 (6.7) 
0 0 
4 (2.2) 1 (6.7) 
0 1 (50.0) 
0 0 
0 0 
0 0 
23 (53.5) 2 (100.0) 
0 0 
1 (2.3) 1 (50 0) 
0 0 
0 0 
0 0 
7 (20.6) 
4 (11.8) 
4 (11.8) 
4 (11.8) 
28 (82.3) 
9 (26.5) 
0 
8 (23.5) 
0 
4 (11.8) 
9 (100.0) 
1 (11.1) 
3 (33.3) 
l(11.1) 
6 (66.6) 
0 
0 
l ( l l . 1 )  
0 
0 
1 (2.2) 
1 (2.2) 
0 
0 
32 (69.6) 
3 (6.5) 
0 
4 (8.7) 
0 
0 
5 (100 (I) 3 (5.1) 
0 3 (5 1) 
0 3 (5.1) 
0 3 (5.1) 
4 (80.0) 47 (79.7) 
0 6 (10.2) 
0 0 
1 (20 0) 7 (1 1 9) 
0 0 
0 0 
~~~~ ~ ~ ~~ ~~~ ~ ~~ ~ 
pos = P-lactamase-positive isolates; neg = P-lactamase-negative isolates; A/C = ainoxicillin pluc clavulanic acid; P/T = piperacsllin plus 
tazobactam. as recommended in the BSAC guidelines [13]; %otal n (“A). 
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from 67.7% to < 12.9%. Among non-p-lactamase 
producers, the incidence of amoxicillin resistance (6%) 
was also decreased with the addition of clavulanic acid 
(< 4.4%; Table 5). 
DISCUSSION 
This study has demonstrated that H. inzuenzne isolates 
from Scotland remain largely sensitive to a range of 
antimicrobial agents, including the p-lactams cefixime 
and cefuroxime, the p-lactam/p-lactamase-inhibitor 
combinations piperacillin plus tazobactam and amoxi- 
cillin plus clavulanic acid, the 4-quinolone cipro- 
floxacin and the macrolide azithromycin. 
Among all centers, the H. injuenzae isolates were 
least sensitive to cefaclor (MIC50 = 4 mg/L; MIC9o = 
8 mg/L). Cefaclor has enjoyed extensive use worldwide 
[17] and studies have reported sustained activity against 
P-lactamase-producing H. injuenzae [17,18]. Interest- 
ingly, a huge difference in the prevalence of resistance 
to this agent was identifed, as determined by breakpoint 
value, when a low breakpoint value of 2 mg/L (71.8%) 
was used compared with a high breakpoint value of 
8 mg/L (9.9%). Although some H. injuenzae isolates 
were highly resistant to amoxicillin (range 0.06 mg/L 
to >128 mg/L), the overall level of resistance to this p- 
lactam was 15%, indicating that there has been little 
change in the incidence of anioxicillin resistance among 
H .  injuenzae in Scotland. Reid and colleagues reported 
14.3% ampicillin resistance in H. injuenzae isolated in 
Scotland in 1983/1984 [19]. Similarly, in a UK study 
of H. injuenzae, 14.6% resistance to ampicillin was 
identified [4]. The prevalence of amoxicillin resistance 
is, however, higher than previously reported. In 1987, 
ampicillin resistance was 7.8% in a study of 23 
laboratories in the UK [20] and, in Ireland, 10.9% 
ampicillin resistance was reported by Howard and 
Williams [21]. In contrast, other studies have shown an 
increase in the prevalence of diminished susceptibility 
to ampicillin [12,17,22]; among Canadian isolates, 29% 
were ampicillin-resistant. 
As reported elsewhere [17], in the present study, 
the presence of clavulanic acid notably increased the 
efficacy of amoxicillin. In all centers, the MIC90 value 
of amoxicillin was reduced from 2 mg/L to 1 mg/L 
when combined with clavulanic acid. Furthermore, 
when the prevalence of resistance, as determined 
by breakpoint value, was considered, resistance to 
amoxicillin among p-lactamase producers (67.7%) and 
non-P-lactamase producers (6%) was reduced to 
5 12.9% and 5 4.4%, respectively, in the presence of 
clavulanic acid. Although the mechanism of inhibitor 
resistance among non-P-lactamase producers was not 
investigated in the present study, changes in membrane 
permeability have been found to be associated with 
resistance to p-lactam@-lactamase-inhibitor combin- 
ations [19]. As would be expected, therefore, this type 
of resistance would not be circumvented by the use of 
amoxicillin plus clavulanic acid. In assessing the overall 
level of resistance, clavulanic acid was more efficacious 
with amoxicillin when tested at either a 2:l ratio or 
with clavulanic acid fixed at 2 mg/L (4.2%) than at a 
4:l ratio (5.6%). 
In comparison to the other p-lactam agents tested, 
cefuroxime resistance appeared to have increased. In a 
study reported by Burns and coworkers, the MIC90 of 
cefuroxime among ampicillin-susceptible strains was 
0.01 mg/L [3] whereas, in the present study, the MIC90 
of cefuroxime in all centers was 1 mg/L. Cefixime i s  
an oral cephalosporin shown to be stable in the 
presence of a wide range of P-lactamases. Isolates of H. 
injuenzae were inhibited by 2 mg/L of cefixime in a 
study by Powell and Williams [23]. In the present study, 
cefixime was inhibitory at 0.25 mg/L. All of the isolates 
were completely sensitive to piperacillin in combin- 
ation with tazobactam, a finding which was also 
recognized in a multicenter study examining the in- 
vitro activity of this combination [24]. The highest 
incidence of p-lactam resistance among both non-p- 
lactamase and P-lactamase producers was to cefaclor. 
Indeed, the BSAC guidelines [I31 state that H. 
injuenzae may be intrinsically resistant to this anti- 
microbial agent. 
The prevalence of resistance to trimethoprim was 
4.2%. In other studies, similar incidences of trimetho- 
prim resistance in H .  injuenzae have been reported: 
4.2% [20]; 5.1% [21]; and 6.8% [5]. A number of other 
investigations have revealed the 4-quinolone agents - 
in particular, ciprofloxacin - to be highly active against 
H. injuenzae [25]. This agent performed particularly 
well against the H .  injuenzae isolates currently investi- 
gated. Indeed, a single isolate from Aberdeen was 
resistant to ciprofloxacin with an MIC value of 4 
mg/L. Although rare, 4-quinolone resistance has been 
previously reported in H. injuenzae and, in particular, 
from this specific center 126,271. In the present study, 
higher levels of overall antibiotic resistance were 
identified in the organisms isolated from Dundee. The 
reported values may, however, be distorted by the 
hsproportionate contribution of H. injuenzae isolates 
from this particular center. 
In the present study, TEM-1 accounted for 78.8% 
of the p-lactamases identified. This is not surprising as 
TEM-1 i s  the most frequently identified P-lactaniase 
among clinical isolates of H. injuenzae. In 1981, a new 
p-lactamase in H. i@ienzae, ROB-I, was character- 
ized and has since been isolated in other surveys of this 
organism [9]. Indeed, this enzyme now accounts for a 
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significant amount of p-lactamase-positive H .  ir?fluenzae 
in the comriiunity 19,121, although this P-lactainase was 
not found among the isolates currently investigated. 
VAT-1, however, a novel p-lactamase [lo1 specific to 
H .  influenzac, was isolated on only eight occasions. It  is 
uncertain whether this p-lactaniase will increase in 
prevalence. The number of p-lactaniasc-positive isolates 
increased after prolonged exposure to nitrocephin, 
suggesting that current testing procedures may under- 
estimate the occurrence of p-lactarnase-producing H. 
inf luenme. It should be emphasized, however, that such 
weak p-lactamase-producing strains are not believed to 
be clinically significant as the MIC of amoxicillin was 
< 1 mg/L for each of these strains. 
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